Meghmani Finechem Limited (MFL), a leading manufacturer of Chlor-Alkali and value-added Derivatives, Q1 FY22 revenue grew 111% to reach Rs. 290 crore whereas profit was up by 107% to reach Rs. 37 crore.  Capacity utilization across all the divisions is highest ever. The company achieved 75% capacity utilisation of Hydrogen Peroxide in the 2nd year of operations. On YoY, ECU realisation for Caustic Soda improved by 12% and CMS sales realisation improved by 40% whereas H2O2 sales realisation improved by 36% QoQ The expansion plan of Epichlorohydrin (50 KTPA), CPVC (30 KTPA), Caustic Soda (106 KTPA) and CPP (36 MW) are going as per schedule. Commenting on the results Maulik Patel, Chairman and Managing Director, MFL said, “The listing of MFL as a separate entity is a key milestone in our journey towards sustainable and long term value creation. We at MFL have a singular focus of creating a world-class chemicals company with a strong focus on sustainability.”  “Our highly capable management team and our motivated workforce are ensuring that we continue our strong growth trajectory. This is also evident from the fact that we delivered one of our best operational and financial performance in Q1 FY22, despite an extremely challenging environment on account of the 2nd wave of Covid. Our revenue and profitability both grew 2.1x compared to Q1 of last year. We have been able to maintain our balance sheet strength and our growth has primarily been financed through strong internal cash flows. We hope to maintain similar momentum in the coming quarter and are confident of delivering superior stakeholder value,” added Patel.  Meghmani Finechem Limited made a stellar debut on stock exchanges on 18th August, as the stock got listed at Rs. 406.45 on NSE, a 194% premium to its opening price of Rs. 138.25 (closing price of its parent company, Meghmani Organics Ltd. on 17th May, 2021). 

Register Now to Attend NextGen Chemicals & Petrochemicals Summit 2024, 11-12 July 2024, Mumbai